MADISON, Wis.--(BUSINESS WIRE)--Mithridion, Inc., a biopharmaceutical company focusing on serious central nervous system (CNS) disorders, announced today results from a Phase I pharmacokinetic and clinical study of MCD-386, its lead drug candidate for Alzheimer’s disease (AD). MCD-386 is an M1 selective muscarinic agonist with “first-in-class” potential for improving memory and cognition symptoms, and for disease-modifying effects (or stopping disease progression) in AD.
